<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266954</url>
  </required_header>
  <id_info>
    <org_study_id>113124</org_study_id>
    <nct_id>NCT01266954</nct_id>
  </id_info>
  <brief_title>An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer</brief_title>
  <official_title>An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the potential dose response relationship between the&#xD;
      pharmacokinetics of GSK2141795 and [18F] FDG PET pharmacodynamic markers of glucose&#xD;
      metabolism in tumor tissue. Three to six subjects will be enrolled in each cohort and dosed&#xD;
      with repeat escalating doses of GSK2141795. [18F] FDG PET imaging and optional tumor biopsies&#xD;
      will be done prior to initiation of dosing and sequentially at select time points during the&#xD;
      first five weeks of dosing. The maximal dose of a given schedule evaluated in this study will&#xD;
      not exceed the maximal tolerated dose established in the first-time-in-human trial PCS112689&#xD;
      for the same schedule.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2010</start_date>
  <completion_date type="Actual">September 1, 2011</completion_date>
  <primary_completion_date type="Actual">September 1, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of GSK2141795 in the blood (ng/ml) from baseline</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The net unidirectional uptake of FDG (Ki) from baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in size of tumor from baseline (RECIST Criteria)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three to six patients on a medium dose of GSK2141795 for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2141795</intervention_name>
    <description>GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models</description>
    <arm_group_label>Stage 1</arm_group_label>
    <arm_group_label>Stage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving written informed consent&#xD;
&#xD;
          2. Females of non-childbearing potential, 18 years or older with ovarian cancer&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or&#xD;
             persistent ovarian cancer&#xD;
&#xD;
          4. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or&#xD;
             persistent uterine or gastro-oesophageal tumors (these tumor types will only be&#xD;
             included if there is poor enrollment of patients with ovarian cancer)&#xD;
&#xD;
          5. Disease at least 2 cm suitable for assessment by imaging&#xD;
&#xD;
          6. Performance Status score of 0, 1 or 2 according to the Eastern Cooperative Oncology&#xD;
             Group scale&#xD;
&#xD;
          7. Adequate organ systems function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, radiotherapy, or immunotherapy within 28 days prior to the first dose of&#xD;
             GSK2141795&#xD;
&#xD;
          2. Use of an investigational anti-cancer drug within 28 days or five half-lives,&#xD;
             whichever is shorter, prior to the first dose of GSK2141795&#xD;
&#xD;
          3. Current use of a prohibited medication&#xD;
&#xD;
          4. Anticoagulants at therapeutic doses are permitted only after consultation with the GSK&#xD;
             Medical Monitor&#xD;
&#xD;
          5. Presence of active gastrointestinal disease or other condition that could affect&#xD;
             gastrointestinal absorption&#xD;
&#xD;
          6. Any major surgery within the last four weeks of screening&#xD;
&#xD;
          7. Unresolved toxicity greater than or equal to Grade 2 from previous anti-cancer therapy&#xD;
&#xD;
          8. Previously diagnosed diabetes mellitus&#xD;
&#xD;
          9. Current use of oral corticosteroids, with the exception of inhaled or topical&#xD;
             corticosteroids&#xD;
&#xD;
         10. Any serious or unstable pre-existing medical, psychiatric, or other condition&#xD;
&#xD;
         11. Symptomatic or untreated CNS metastases or leptomeningeal involvement&#xD;
&#xD;
         12. Evidence of severe or uncontrolled systemic diseases&#xD;
&#xD;
         13. QTc interval â‰¥ 470 msecs&#xD;
&#xD;
         14. Other clinically significant ECG abnormalities&#xD;
&#xD;
         15. History of myocardial infarction, acute coronary syndromes&#xD;
&#xD;
         16. Class III or IV heart failure&#xD;
&#xD;
         17. Pregnant or Lactating patients&#xD;
&#xD;
         18. History of hepatitis B or C or HIV&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>18F FDG</keyword>
  <keyword>PK</keyword>
  <keyword>PET</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>PD</keyword>
  <keyword>AKT Inhibitor</keyword>
  <keyword>GSK2141795</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

